Skip to Main Content

Paper Details

The prevalence of homologous recombination deficiency (HRD) in various solid tumors and the role of HRD as a single biomarker to immune checkpoint inhibitors.
J Cancer Res Clin Oncol
5
2022
ARID1A, ATM, BARD1, BRCA2, BTC, CRC, GC, GI cancers, GU cancer, HCC, HRD, Homologous recombination deficiency, PC, Patients, Tumor, advanced solid tumor, biliary tract cancer, cancer, colorectal cancer, gastrointestinal (GI, genitourinary (GU, hepatocellular carcinoma, homologous recombination deficiency, melanoma, pancreatic cancer, patients, rare cancer, sarcoma, solid tumor, solid tumors
Author NameAffiliation
Jeeyun LeeSamsung Medical Center, Sungkyunkwan University School of Medicine
Joon Oh ParkSamsung Medical Center, Sungkyunkwan University School of Medicine
Kyoung-Mee KimSamsung Medical Center, Sungkyunkwan University School of Medicine
Sung Tae KimSamsung Medical Center, Sungkyunkwan University School of Medicine
Sung Tae KimSamsung Medical Center, Sungkyunkwan University School of Medicine
  • 1 - 5

Datasets

Release 1.2